Mabpharm (2181) Stock Overview
A biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2181 from our risk checks.
2181 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Mabpharm Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.54 |
| 52 Week High | HK$0.94 |
| 52 Week Low | HK$0.25 |
| Beta | 1 |
| 1 Month Change | 3.85% |
| 3 Month Change | -32.50% |
| 1 Year Change | 66.15% |
| 3 Year Change | 35.00% |
| 5 Year Change | -54.24% |
| Change since IPO | -55.37% |
Recent News & Updates
Mabpharm Limited's (HKG:2181) Low P/S No Reason For Excitement
Oct 31
Here's Why Mabpharm (HKG:2181) Can Afford Some Debt
Sep 29Why Investors Shouldn't Be Surprised By Mabpharm Limited's (HKG:2181) Low P/S
Jul 28Recent updates
Mabpharm Limited's (HKG:2181) Low P/S No Reason For Excitement
Oct 31Here's Why Mabpharm (HKG:2181) Can Afford Some Debt
Sep 29Why Investors Shouldn't Be Surprised By Mabpharm Limited's (HKG:2181) Low P/S
Jul 28We Think Some Shareholders May Hesitate To Increase Mabpharm Limited's (HKG:2181) CEO Compensation
Jun 11Is Mabpharm (HKG:2181) Using Too Much Debt?
Mar 27There's Reason For Concern Over Mabpharm Limited's (HKG:2181) Massive 45% Price Jump
Feb 19Investors Don't See Light At End Of Mabpharm Limited's (HKG:2181) Tunnel
Dec 22Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now
Jun 14More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%
Jan 24Mabpharm (HKG:2181) Is Making Moderate Use Of Debt
Oct 20Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Jan 18Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation
Oct 07Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation
Apr 28Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?
Mar 03We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate
Jan 27
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?
Dec 09Shareholder Returns
| 2181 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 3.8% | 8.0% | 1.8% |
| 1Y | 66.2% | 115.1% | 35.8% |
Return vs Industry: 2181 underperformed the Hong Kong Biotechs industry which returned 115.1% over the past year.
Return vs Market: 2181 exceeded the Hong Kong Market which returned 35.8% over the past year.
Price Volatility
| 2181 volatility | |
|---|---|
| 2181 Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in HK Market | 14.5% |
| 10% least volatile stocks in HK Market | 3.1% |
Stable Share Price: 2181 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2181's weekly volatility has decreased from 16% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 383 | Hao Wang | www.mabpharm.cn |
Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. The company offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment of ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, Crohn’s disease in adults and pediatric patients aged above 6 years old, fistula Crohn’s disease, and psoriasis. It also develops CMAB807/CMAB807X that has completed Phase III clinical trial for the treatment of osteoporosis, tumor bone metastasis, and giant-cell tumor of bone; CMAB819 that has completed Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; and CMAB015, a biosimilar candidate for secukinumab to treat psoriasis and ankylosing spondylitis that is in Phase I clinical trial.
Mabpharm Limited Fundamentals Summary
| 2181 fundamental statistics | |
|---|---|
| Market cap | HK$2.19b |
| Earnings (TTM) | -HK$30.26m |
| Revenue (TTM) | HK$466.75m |
Is 2181 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2181 income statement (TTM) | |
|---|---|
| Revenue | CN¥423.93m |
| Cost of Revenue | CN¥57.65m |
| Gross Profit | CN¥366.28m |
| Other Expenses | CN¥393.76m |
| Earnings | -CN¥27.48m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0067 |
| Gross Margin | 86.40% |
| Net Profit Margin | -6.48% |
| Debt/Equity Ratio | 259.4% |
How did 2181 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/01 17:37 |
| End of Day Share Price | 2025/12/01 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mabpharm Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yue-Kwong Lui | Jefferies LLC |